Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) FCF Margin: 2013-2025

Historic FCF Margin for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -400.48%.

  • Coherus Oncology's FCF Margin rose 62424.00% to -400.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 139.88%, marking a year-over-year decrease of 1060.00%. This contributed to the annual value of -7.66% for FY2024, which is 6044.00% up from last year.
  • Per Coherus Oncology's latest filing, its FCF Margin stood at -400.48% for Q3 2025, which was down 109.40% from 4,259.49% recorded in Q2 2025.
  • Coherus Oncology's FCF Margin's 5-year high stood at 6,111.66% during Q1 2024, with a 5-year trough of -1,024.72% in Q3 2024.
  • Moreover, its 3-year median value for FCF Margin was -66.45% (2023), whereas its average is 832.58%.
  • Per our database at Business Quant, Coherus Oncology's FCF Margin soared by 632,402bps in 2024 and then slumped by 651,362bps in 2025.
  • Coherus Oncology's FCF Margin (Quarterly) stood at -71.97% in 2021, then tumbled by 14,862bps to -220.59% in 2022, then surged by 20,641bps to -14.17% in 2023, then surged by 2,569bps to 11.52% in 2024, then soared by 62,424bps to -400.48% in 2025.
  • Its last three reported values are -400.48% in Q3 2025, 4,259.49% for Q2 2025, and -401.96% during Q1 2025.